What is GHRP-6? What it does, benefits and what the evidence shows

GHRP-6 is a synthetic six-amino-acid peptide, one of the first growth hormone-releasing peptides ever made, that prompts the pituitary to release a large, short burst of growth hormone by acting on the same receptor as the hunger hormone ghrelin. We found no approval for it as a treatment. Small human studies from the 1990s and 2000s confirm the growth hormone surge and show it also raises cortisol and prolactin. The muscle, fat-loss and recovery claims that sell it have no controlled human trial behind them, and the increased appetite it is known for has been measured in humans for ghrelin and for its sibling GHRP-2, but we found no human study that measured it for GHRP-6 itself.

What GHRP-6 is and how it works

GHRP-6 is the hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, built partly from non-natural D-form amino acids (Bowers et al., Journal of Clinical Endocrinology & Metabolism, 1990). It came out of Cyril Bowers's group, which reported in 1984 that a small synthetic hexapeptide released growth hormone from pituitary tissue in a dish and in rats, monkeys, lambs and calves, without releasing LH, FSH, TSH or prolactin in the limited studies they ran (Bowers et al., Endocrinology, 1984). Hexarelin, a later compound, was described in the literature as an analog of GHRP-6 (Giustina et al., Journal of Endocrinology, 1995).

For years nobody knew what receptor these peptides hit. In 1996 a receptor found in the pituitary and hypothalamus was cloned and shown to be the target of these synthetic growth hormone secretagogues (Howard et al., Science, 1996). In 1999 the natural partner turned up: a 28-amino-acid peptide from the stomach, named ghrelin, that specifically releases growth hormone through that same receptor (Kojima et al., Nature, 1999). GHRP-6 is, in effect, a small synthetic ghrelin mimic. That is why it does two things at once: it releases growth hormone and, in animals, it stimulates feeding.

Like other members of this family, it does not supply growth hormone; it prompts the body to release its own, and it needs the hypothalamus and pituitary to be talking to each other. In 11 healthy people, a GHRP-6 challenge produced roughly three times the growth hormone output of GHRH, and the two together produced more than the sum of each alone. In 12 patients whose pituitary was functionally disconnected from the hypothalamus, the response to GHRP-6 was almost completely blocked (Popovic et al., Journal of Clinical Endocrinology & Metabolism, 1995).

Approval status

We found no approval for GHRP-6 as a drug anywhere, and no ClinicalTrials.gov record for it. The closest thing to an approved use in this drug class is a different ghrelin-receptor agonist, macimorelin, which the FDA approved in 2017 as a diagnostic test for adult growth hormone deficiency (Macrilen label, DailyMed). GHRP-6 itself was tested for a similar purpose in research settings, described below, but it never became a marketed test that we could find.

What people use it for

What the research actually shows

The growth hormone surge is real

The first human dose-response work was in 18 healthy men. A GHRP-6 bolus raised peak growth hormone from about 1 microgram per liter on placebo to about 69 at the highest dose studied, and given with GHRH it acted synergistically (Bowers et al., Journal of Clinical Endocrinology & Metabolism, 1990). A review by Ghigo and colleagues notes that GHRP-6 was the first hexapeptide extensively studied in humans, that the response shrinks in idiopathic growth hormone deficiency, obesity and hypothyroidism, and that it fades with age but stays larger than the GHRH response into the sixth decade (Ghigo et al., European Journal of Endocrinology, 1997).

None of this shows that a growth hormone spike does anything useful for a healthy adult. A surge is a hormone measurement, not a benefit.

It is not a clean growth hormone signal

In the same 18-man study, prolactin and cortisol rose about twofold at the highest dose studied, though not at lower ones (Bowers et al., 1990). Later work found GHRP-6 is a real activator of the stress axis. In 10 patients with Cushing's disease it raised ACTH and cortisol about as much as the drug desmopressin did (Oliveira et al., Journal of Endocrinological Investigation, 2003). A team even tested it as a way to diagnose adrenal insufficiency; in 49 patients and 20 healthy controls it activated the axis with no detectable side effects, but it was less accurate than the standard insulin tolerance test (Alaioubi et al., Hormone and Metabolic Research, 2010). If you have seen GHRP-6 compared with ipamorelin, this cortisol effect is the usual contrast; see our ipamorelin guide, and the sibling GHRP-2 and hexarelin guides, which describe similar off-target hormone effects.

Diagnostic testing

Because GHRP-6 produces a big spike in healthy people and a small one in growth hormone deficiency, researchers tried it as a diagnostic. In 20 adults with suspected pituitary or adrenal disease, GHRP-6 alone or combined with GHRH picked out every patient with deficiency as defined by the insulin tolerance test, and the only side effect reported was flushing; it was a small study, with 10 patients in each group (Petersenn et al., European Journal of Endocrinology, 2002). An earlier study in short-statured children and adults found the individual results overlapped too much between deficient and normal people to be a clean test, though the response was nearly absent in patients with a severed pituitary stalk (Pombo et al., Journal of Pediatric Endocrinology & Metabolism, 1996). These are small studies, and none produced an approved GHRP-6 test.

What happens with repeated use

The evidence is mixed. In six healthy men, a short run of repeated GHRP-6 doses did not blunt the growth hormone response and raised IGF-I (Hayashi et al., Endocrinologia Japonica, 1991). But the same Ghigo review says the response undergoes partial desensitization (Ghigo et al., 1997), and in six healthy volunteers a GHRP-6 dose measurably reduced the growth hormone response to ghrelin given shortly afterward (Micic et al., European Journal of Endocrinology, 2002). We found no human study that followed muscle, fat or strength over weeks or months with GHRP-6.

Appetite

Since GHRP-6 acts on the ghrelin receptor, hunger is the expected side effect, and the animal work supports it. Injected into the brains of rats, GHRP-6 and ghrelin both stimulated food intake, and the effect was blocked by an NPY receptor antagonist (Lawrence et al., Endocrinology, 2002). In humans, the direct evidence is for its relatives: an intravenous ghrelin infusion raised buffet-meal energy intake by about 28% in nine healthy volunteers (Wren et al., Journal of Clinical Endocrinology & Metabolism, 2001), and GHRP-2 raised it by about 36% in seven lean men (Laferrère et al., 2005; see our GHRP-2 guide). That makes increased appetite a reasonable expectation for GHRP-6, but we did not find a human study that measured it.

Stroke: the one recent human trial

The most recent human trials of GHRP-6 tested it combined with epidermal growth factor (EGF), given intravenously to people in the hours after an ischemic stroke. A phase I/II trial of 36 patients, registered with the Cuban Public Registry of Clinical Trials, reported the combination was safe and had favorable functional outcomes, which supported a larger trial (Hernández-Bernal et al., Frontiers in Neurology, 2024). The phase III trial, published in 2026, enrolled 188 patients and missed its primary endpoint: there were no differences between treated and control patients in disability, function or survival. Serious adverse events occurred in 48 of 188 patients (30 of 95 in the treated group and 18 of 93 in the control group, a difference that was not statistically significant), none judged treatment-related. In a small subgroup of 27 patients with severe stroke, treated patients had less disability and lower mortality risk, which the authors called a signal that warrants further study (Hernández-Bernal et al., Journal of Clinical Neuroscience, 2026). Both trials were open-label, and both tested the combination, so they cannot tell you what GHRP-6 does on its own.

Heart, gut and other organs

Several rodent studies report protective effects. GHRP-6 reduced gut and liver damage in rats after blood flow was cut off and restored (Cibrián et al., Clinical Science, 2006), prevented heart damage from the chemotherapy drug doxorubicin in rats (Berlanga-Acosta et al., Frontiers in Pharmacology, 2024), and improved heart remodeling in rats after an induced heart attack (Wang et al., Pharmaceuticals, 2026). The author lists overlap (Berlanga-Acosta, or Berlanga in the 2006 paper, is listed on each), so this looks like one group's work rather than independent replication. None of it has been shown in people.

Everything else

We found no controlled human trial of GHRP-6 for muscle growth, fat loss, tendon or joint healing, sleep, skin or anti-aging. Those claims rest on the growth hormone mechanism and on anecdote.

Side effects and risks

There is no long-term human safety database for GHRP-6. What the record shows:

• Cortisol and prolactin. Both rose in healthy men at the highest dose studied (Bowers et al., 1990), and ACTH and cortisol rose in patients (Oliveira et al., 2003). Nobody has studied what prolonged exposure to that does.
• Flushing. The only side effect reported in the diagnostic study (Petersenn et al., 2002). Those were short clinic tests, not a safety profile.
• FDA's view. GHRP-6 is on FDA's list of bulk drug substances that may present significant safety risks for compounding (outsourcing-facility category), added September 29, 2023. FDA cites potential immunogenicity from aggregation and peptide-related impurities, and says the limited available data show safety concerns including a potential effect on cortisol and a rise in blood glucose from reduced insulin sensitivity (FDA, page current as of April 22, 2026). Those are FDA's words about limited data, not confirmed harms.
• Appetite. Expected from the mechanism; see above.

There is also a documented quality problem in this corner of the market. Unlabelled powders seized by Danish authorities turned out to be analogs of GHRP-2, GHRP-6, ipamorelin and modified GRF 1-29, each with an extra glycine on the end, which meant standard analytical methods had to be updated to catch them (Gajda et al., Drug Testing and Analysis, 2019). That is a small case series, not a market survey, but it says a label is not proof of what is inside.

What the lab tests show

As of September 29, 2026, VendorVerify's database has no lab results for GHRP-6. That doesn't mean vials are good or bad; it means nobody has submitted a report we can count. If you have had a GHRP-6 vial tested, submitting the report is the fastest way to change that, and the first few reports will tell buyers more than any guess can.

Because we don't have enough lab data on this compound to rank vendors for it, here are the highest-ranked vendors across all compounds right now. A vendor's overall record is a signal, not a guarantee for a compound they have never had tested.

Buying smarter

With no compound-specific data, lean on the general checks. Look at each vendor's full record and how many reports sit behind the score, and treat a vendor-posted COA as a starting point (how to read a peptide COA, fake peptide COAs). An independent identity, purity and quantity test on your own vial is worth paying for on a compound with no track record in our data, especially given the modified-analog finding above; how to get a peptide tested walks through it, and endotoxin in research peptides covers when to add that test.

If a report comes back with a fail, stop using that batch, tell anyone who bought from the same run, bring the report to the vendor, and submit it to VendorVerify. Buyers researching GHRP-6 often also look at GHRP-2, hexarelin, ipamorelin, sermorelin and CJC-1295. Our peptide hub lists every compound we track, and what are grey market peptides explains the market itself.

Database figures are from VendorVerify as of September 29, 2026. This isn't medical advice; GHRP-6 is sold for research use only, and we found no approval for it as a drug.